Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Top Performance

Predictions

sell
MorphoSys AG

Start price
Target price
Perf. (%)
€16.57
05.09.22
-
05.10.26
293.97%
11.03.24

Probably not worthwhile Investment
Lutz69 
05.09.22 50%
sell
Quoin Pharmaceuticals Ltd. ADR

Start price
Target price
Perf. (%)
€3.06
03.09.22
-
03.09.23
-86.05%
24.04.23

Risky Investment
Lokrim 
03.09.22 20%
buy
Invitae Corp

Start price
Target price
Perf. (%)
€2.76
02.09.22
-
02.09.23
-10.51%
27.09.22

Could be very worthwhile Investment >20% year
Wolf_of_WS 
02.09.22 50%
buy
Invitae Corp

Start price
Target price
Perf. (%)
€3.32
26.08.22
-
26.08.23
-17.03%
03.09.22

Could be very worthwhile Investment >20% year
Global_Player 
26.08.22 50%
buy
Bausch Health Companies Inc.

Start price
Target price
Perf. (%)
€5.40
23.08.22
-
23.08.23
29.96%
09.09.22

Capable Management
Probably not worthwhile Investment
Revenue decline/stagnation expected
efeu 
23.08.22 50%
buy
Mirati Therapeutics Inc.

Start price
Target price
Perf. (%)
€76.50
21.08.22
€230.00
21.08.23
6.54%
04.09.22

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Probably not worthwhile Investment
Lower EBIT Margin than peer group
Ruckelsbuckel 
21.08.22 50%
sell
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€214.90
21.08.22
€87.00
21.08.23
-3.44%
04.09.22

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
dimontalban 
21.08.22 60%
sell
Invitae Corp

Start price
Target price
Perf. (%)
€3.50
21.08.22
€1.00
21.08.23
-21.28%
04.09.22

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
dimontalban 
21.08.22 50%
buy
PTC Therapeutics Inc.

Start price
Target price
Perf. (%)
€51.50
16.08.22
-
16.08.23
-27.77%
16.08.23

Saftman 
16.08.22 50%
buy
Neurocrine Bioscience

Start price
Target price
Perf. (%)
€104.86
16.08.22
-
16.08.23
-6.73%
16.08.23

Saftman 
16.08.22 50%
buy
QIAGEN NV

Start price
Target price
Perf. (%)
€48.30
12.08.22
€55.00
12.08.23
-17.99%
13.08.23

fmoos 
12.08.22 50%
buy
Global Blood Therapeutics Inc

Start price
Target price
Perf. (%)
€64.36
10.08.22
-
10.08.23
6.49%
10.08.23

Saftman 
10.08.22 50%
buy
Amicus Therapeutics Inc.

Start price
Target price
Perf. (%)
€12.10
10.08.22
-
10.08.23
3.34%
10.08.23

Saftman 
10.08.22 50%
buy
MorphoSys AG

Start price
Target price
Perf. (%)
€22.29
09.08.22
€28.00
09.08.23
24.14%
10.08.23

efeu 
09.08.22 50%
buy
Aphria Inc.

Start price
Target price
Perf. (%)
€12.71
08.08.22
-
08.08.26
-
11.03.24

Could be worthwhile Investment >10% per year
Lutz69 
08.08.22 50%
buy
MorphoSys AG

Start price
Target price
Perf. (%)
€23.24
04.08.22
€30.00
04.08.23
-3.31%
06.08.22

carmelinchen 
04.08.22 50%
buy
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€210.00
04.08.22
-
04.08.23
-17.71%
04.08.23

Joe130978 
04.08.22 50%
buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€2.91
03.08.22
€3.30
03.08.23
-12.37%
13.10.22

Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Risky balance sheet
geldnutzer 
03.08.22 50%
buy
Teladoc Health Inc

Start price
Target price
Perf. (%)
€34.89
29.07.22
-
29.07.23
-26.25%
29.07.23

Joe130978 
29.07.22 50%
buy
Sartorius AG VZO

Start price
Target price
Perf. (%)
€418.20
22.07.22
€550.00
22.07.23
-23.00%
30.05.23

edgaaar 
22.07.22 50%
buy
Invitae Corp

Start price
Target price
Perf. (%)
€2.86
12.07.22
€2.10
12.07.23
-54.35%
11.03.23

Could be worthwhile Investment >10% per year
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
geldnutzer 
12.07.22 60%
sell
Bausch Health Companies Inc.

Start price
Target price
Perf. (%)
€8.45
11.07.22
-
11.07.23
-39.77%
04.08.22

Capable Management
Probably not worthwhile Investment
Revenue decline/stagnation expected
efeu 
11.07.22 50%
buy
Repligen Corp.

Start price
Target price
Perf. (%)
€173.28
09.07.22
-
09.07.23
-24.17%
09.07.23

Joe130978 
09.07.22 50%
buy
Evotec SE

Start price
Target price
Perf. (%)
€24.04
04.07.22
€30.00
04.08.22
19.97%
05.08.22

kaufmeister 
04.07.22 50%
buy
Evotec SE

Start price
Target price
Perf. (%)
€23.21
15.06.22
-
15.06.23
-5.47%
16.06.23

DirectorDealer 
15.06.22 50%